Zenas BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZBIO research report →
Range $32 – $32
Price Chart
About the company
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia.
- CEO
- Leon Oliver Moulder Jr.
- IPO
- 2024
- Employees
- 167
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on ZBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.00B
- P/E
- -3.29
- PEG
- 0.04
- P/S
- 1996.28
- P/B
- 8.08
- EV/EBITDA
- -4.43
- Div Yield
- 0.00%
- Gross Margin
- -5972.60%
- Op Margin
- -47557.30%
- Net Margin
- -48438.40%
- ROE
- -189.68%
- ROIC
- -74.69%
Latest fiscal year · YoY change
- Revenue
- $10.00M+100.0%
- Gross Profit
- $10.00M+107.5%
- Op Income
- $-211,385,000
- Net Income
- $-377,737,000-140.6%
- EPS
- $-8.44-124.5%
- OCF Growth
- -44.0%
- FCF Growth
- -43.9%
- 52W High
- $44.60
- 52W Low
- $13.50
- 50D MA
- $27.53
- 200D MA
- $26.04
- Beta
- -1.01
- RSI (14)
- 56
- Avg Volume
- 832.08K
No earnings-call transcripts are available for ZBIO yet.
- Free Float
- 23.4%
- Shares Outstanding
- 63.13M
- Float Shares
- 14.80M
of shares held by institutions
144 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 9.51M | ▲ 424.70K |
| Sr One Capital Management, LP | 5.04M | 0 |
| Nea Management Company, LLC | 4.02M | 0 |
| Enavate Sciences Gp, LLC | 3.92M | 0 |
| Federated Hermes, Inc. | 3.12M | ▼ 10.23K |
| Blackrock, Inc. | 2.69M | ▲ 648.68K |
| Capital International Investors | 2.50M | ▲ 68.91K |
| Polar Capital Holdings PLC | 2.41M | ▼ 135.67K |
| Fairmount Funds Management LLC | 2.36M | 0 |
| State Street Corp | 2.06M | ▲ 584.18K |
| Nvp Associates, LLC | 1.84M | 0 |
| Wellington Management Group Llp | 1.59M | ▲ 347.77K |
Held by 180 ETFs
Biggest fund positions in ZBIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 15, 26 | Nunn Jason Raleigh | other | 18,500 |
| Jun 15, 26 | Lu Hongbo | other | 18,500 |
| Jun 15, 26 | MOULDER LEON O JR | other | 500,000 |
| Jun 15, 26 | ORLOFF JOHN J | other | 18,500 |
| Jun 15, 26 | von Moltke Lisa | other | 150,000 |
| Jun 15, 26 | Allen Patricia L | other | 18,500 |
| Jun 15, 26 | Boylan James P | other | 18,500 |
| Jun 15, 26 | ENRIGHT PATRICK G | other | 18,500 |
| Jun 15, 26 | Farmer Joseph L | other | 175,000 |
| Feb 5, 26 | Farmer Joseph L | other | 974 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZBIO coverage
Recent articles, reports, and earnings notes.
No research on ZBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZBIO report →Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Aug 18
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 13
Financial Review: Arcturus Therapeutics (NASDAQ:ARCT) vs. Zenas BioPharma (NASDAQ:ZBIO)
defenseworld.net · Jul 28
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jul 17
Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise
seekingalpha.com · Jul 14
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
fool.com · Jun 21
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jun 17
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
globenewswire.com · Jun 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.